Literature DB >> 24363391

Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".

Rob Aarnoutse1, Carolien Ruesen, Erlina Burhan, Reinout van Crevel, Rovina Ruslami.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24363391      PMCID： PMC3910713          DOI： 10.1128/AAC.01651-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy.

Authors:  J B Mehta; H Shantaveerapa; R P Byrd; S E Morton; F Fountain; T M Roy
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

2.  Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.

Authors:  M E Kimerling; P Phillips; P Patterson; M Hall; C A Robinson; N E Dunlap
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

3.  Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors:  Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal:  Clin Infect Dis       Date:  2005-04-14       Impact factor: 9.079

4.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

5.  Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors.

Authors:  M Narita; M Hisada; B Thimmappa; J Stambaugh; E Ibrahim; E Hollender; D Ashkin
Journal:  Clin Infect Dis       Date:  2001-01-25       Impact factor: 9.079

6.  Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Authors:  Erlina Burhan; Carolien Ruesen; Rovina Ruslami; Arum Ginanjar; Hadiarto Mangunnegoro; Purwantyastuti Ascobat; Rogier Donders; Reinout van Crevel; Rob Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

7.  Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.

Authors:  K-C Chang; C-C Leung; W-W Yew; K-M Kam; C-W Yip; C-H Ma; C-M Tam; E C-C Leung; W-S Law; W-M Leung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-24       Impact factor: 3.267

8.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.